Purpose: This study was conducted to determine the efficacy of taxane-based regimens in patients with metastatic breast cancer pre-treated with taxanes in adjuvant/Neo-adjuvant treatment in correlation with breast cancer subtypes Methods: The study included 173 patients diagnosed with metastatic/locally recurrent breast cancer between November 2018 and November 2020; patients received Taxane-based protocol as re-challenge or non-Taxane systemic treatment as per institute protocol. Results: Of 173 patients, 90 (52%) received Taxane-based therapies, 54 (31.2%) received Capecitabine-based therapies, and 29 (16.8%) Carboplatin/ Gemcitabine. Although the response rate was more significant in the taxane rechallenge group (65%) in the luminal subgroup, no statistical significance between the 2 groups was determined in the non-luminal breast cancer subtype. The ORR (in both Luminal and non-luminal subtypes) for the taxane re-challenge regimen was 58.9%, compared to 50.6% in the nontaxane-group, with no significant difference in ORR between re-challenge and non-taxane-based treatment at metastatic setting. A non-significant difference was found in PFS between both chemotherapy groups in metastatic settings, with a median of 13 months in both study arms. Re-challenge showed a more significant incidence of neuropathy than the non-taxane group, although more significant GIT and skin toxicity were reported in the non-taxane-based group (0.001). Conclusion: Rechallenging with taxanes in a metastatic setting after (neo) adjuvant taxane exposure seems to be a reasonable option with high response rates, especially when rapid response is needed in the luminal subtype. [ABSTRACT FROM AUTHOR]